{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:20:46Z","timestamp":1789881646273,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The randomized, double\u2010blind, double\u2010dummy, phase 3b <jats:styled-content style=\"fixed-case\">RELIEF<\/jats:styled-content> trial evaluated polycythaemia vera (<jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>)\u2010related symptoms in patients who were well controlled with a stable dose of hydroxycarbamide (also termed hydroxyurea) but reported <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>\u2010related symptoms. Patients were randomized 1:1 to ruxolitinib 10\u00a0mg <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a054) or hydroxycarbamide (prerandomization dose\/schedule; <jats:italic>n<\/jats:italic>\u00a0=\u00a056); crossover to ruxolitinib was permitted after Week 16. The primary endpoint, \u226550% improvement from baseline in myeloproliferative neoplasm \u2010symptom assessment form total symptom score cytokine symptom cluster (<jats:styled-content style=\"fixed-case\">TSS<\/jats:styled-content>\u2010C; sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at Week 16, was achieved by 43\u00b74% vs. 29\u00b76% of ruxolitinib\u2010 and hydroxycarbamide\u2010treated patients, respectively (odds ratio, 1\u00b782; 95% confidence interval, 0\u00b782\u20134\u00b704; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b7139). The primary endpoint was achieved by 34% of a subgroup who maintained their hydroxycarbamide dose from baseline to Weeks 13\u201316. In a post hoc analysis, the primary endpoint was achieved by more patients with stable screening\u2010to\u2010baseline <jats:styled-content style=\"fixed-case\">TSS<\/jats:styled-content>\u2010C scores (ratio\u00a0\u2264\u00a02) receiving ruxolitinib than hydroxycarbamide (47\u00b74% vs. 25\u00b70%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b70346). Ruxolitinib treatment after unblinding was associated with continued symptom score improvements. Adverse events were primarily grades 1\/2 with no unexpected safety signals. Ruxolitinib was associated with a nonsignificant trend towards improved <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>\u2010related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement.<\/jats:p>","DOI":"10.1111\/bjh.14382","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T12:45:24Z","timestamp":1478609124000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double\u2010blind, double\u2010dummy, symptom study (RELIEF)"],"prefix":"10.1111","volume":"176","author":[{"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[{"name":"Mayo Clinic Cancer Center Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms AOU Careggi University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center Westwood KS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Zachee","sequence":"additional","affiliation":[{"name":"ZNA Stuivenberg Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Garg","sequence":"additional","affiliation":[{"name":"Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lyons","sequence":"additional","affiliation":[{"name":"Texas Oncology and US Oncology Research San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Haemostaseology, and Stem Cell Transplantation Faculty of Medicine RWTH Aachen University Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"University of Lincoln and United Lincolnshire Hospital Trust Lincoln UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Byrne","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Hasan","sequence":"additional","affiliation":[{"name":"Sandwell and West Birmingham Hospitals NHS Trust West Bromwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"University of Insubria Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hunter","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhen","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.766732"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387787"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031070"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9337"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.619608"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208500"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4077.4077","article-title":"Hydroxyurea treatment history and quality of life in patients with polycythemia vera: results from the MPN Landmark survey in the United States","volume":"126","author":"Mesa R.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12707"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65\u00a0years","volume":"90","author":"Najean Y.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_18_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v3.0. Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed February 26 2016."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.01.006"},{"issue":"1","key":"e_1_2_8_20_1","article-title":"Conventional therapeutic options have limited impact on MPN symptoms: insights from a prospective analysis of the MPN\u2010SAF","volume":"97","author":"Scherber R.","year":"2012","journal-title":"Haematologica"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23474"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood.V122.21.4070.4070","article-title":"The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT\u2010II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT)","volume":"122","author":"Squires M.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23295"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-551929"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14382","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:20:39Z","timestamp":1696252839000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/bjh.14382"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14382","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"assertion":[{"value":"2016-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}